RedHill Bio gains 6% after Talicia shows efficacy in eradicating H. pylori infection
Dec. 02, 2021 7:41 AM ETRedHill Biopharma Ltd. (RDHL)
By: Mamta Mayani, SA News Editor
RedHill Biopharma (NASDAQ:RDHL) announces the publication of a new study in the journal GastroHep, showing the high efficacy of Talicia in eradicating H. pylori irrespective of patient BMI and level of obesity in clinical trials.
RDHL shares up 6.3% premarket at $2.89.
This new publication, describing a post-hoc analysis of data from 269 patients from the ERADICATE Hp and ERADICATE Hp2 Phase 3 clinical trials showed that Talicia maintained high efficacy across all BMI groups compared to the active comparator including in obese and severely obese patients (P<0.0001).
Patients with a BMI between 30-40 kg/m2 and those with BMI >40kg/m treated with Talicia achieved eradication rates of ~90% (88.1% and 90.9% respectively) versus active comparator rates of 62.9% and 31.8% respectively – the active comparator demonstrated nearly 50% lower efficacy in the severely obese group.
No cases of rifabutin resistance were identified in this study.
Generally, no differences were identified in the safety of Talicia across BMI groups, consistent with its overall safety profile.
H. pylori is a bacterial infection that affects ~35% of the U.S. population
News 
Market Data 
Discover 
